Skip to content

Platelet Rich Plasma Study With Meniscal Repair

Prospective, Double Blind, Randomized Trial: Meniscal Repair With or Without Augmentation Utilizing Platelet Rich Plasma.

Status
Withdrawn
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01991353
Enrollment
0
Registered
2013-11-25
Start date
2015-07-31
Completion date
2018-01-31
Last updated
2016-04-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Meniscus Lesion

Keywords

Knee, meniscus, platelet rich plasma

Brief summary

This study will compare meniscal healing with or without platelet rich plasma. The assessments will include validated, disease specific, patient oriented outcome measures, MRI arthrogram (MRA). Results of this study will help ascertain whether PRP improves meniscal healing rates. Null Hypothesis: There is no difference in meniscal healing with or without the use of PRP.

Detailed description

The integrity of the meniscus is pivotal to the distribution of joint reaction forces and shock absorption across the knee and meniscal damage can lead to secondary degenerative joint disease. This has lead to treatments directed towards repairing and preserving the meniscus to alter the progression of joint degeneration. Although success rates of meniscal repair are greater when performed in association with anterior cruciate reconstruction, healing rates remain in the 70-80% range for isolated repairs. Therefore, techniques such as the use of fibrin clots, trephining and rasping of the tissues, have been incorporated to improve healing results of meniscal repair. There has been a surge of enthusiasm for the use of Platelet Rich Plasma (PRP) to improve healing rates of soft tissue injuries. Therefore, it may be reasonable to surmise that applying blood products, such as thrombin and platelet rich plasma, to the meniscal repair bed may induce more complete and possibly faster healing.

Interventions

PROCEDUREWith PRP

Following meniscal repair, PRFM will be delivered arthroscopically into the tear site using a portal skid, arthroscopic canula and arthroscopic atraumatic tissue grasper into the interface of the repair site.

PROCEDUREWithout PRP

Standard of care meniscal repair without augmentation.

Sponsors

Fraser Orthopaedic Research Society
Lead SponsorNETWORK

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
No

Inclusion criteria

* complete vertical longitudinal tear \> 10 mm in length * tear located in the vascular portion of the meniscus, classified as either red-red or red-white zones * a stable knee, or a knee that is stabilized with a concurrent ACL reconstruction * unstable peripheral tear that can be displaced toward center of joint * single tear of the medial and/or lateral meniscus * skeletally mature patients 18-60 years of age

Exclusion criteria

* associated significant ligament instability: Grade III MCL, Grade III PCL * discoid meniscus * ACL deficient knee * Outerbridge Grade III or IV cartilage changes on arthroscopy in the involved compartment * Significant degenerative changes on radiographs (Kellgren Lawrence \>/= Grade III) * Associated osteochondral defect that requires treatment * Inflammatory arthropathy (e.g. rheumatoid arthritis) * Non repairable meniscus (ie white zone, irreducible meniscus) * Degenerative meniscus or presence of CPP crystals in meniscus * Underlying bleeding disorder or coagulopathy

Design outcomes

Primary

MeasureTime frameDescription
MRA (magnetic resonance imaging arthrography6 monthsThe primary outcome measures will be assessment of meniscal healing integrity using magnetic resonance imaging arthrography six months post repair.

Secondary

MeasureTime frameDescription
WOMET - Western Ontario Meniscal Outcome MeasureBaseline, 3 months, 6 months 12 monthsThe WOMET is a disease-specific validated tool designed to evaluate HRQOL (Health Related Quality of Life) in patients with meniscal pathology (meniscal tears or in patients who have undergone meniscal repair or resection). In this subset of patients with meniscal pathology, the WOMET has been found to be reliable, valid and responsive. The WOMET has 16 items including the domains of physical symptoms, sports/recreation/work/lifestyle, and emotions. It demonstrated adequate content and construct validity when compared with other measures. Test-retest reliability was assessed and was found to be high, with an intraclass correlation coefficient of 0.833.
VAS Pain Score - Visual Analog ScaleBaseline, Post-op Day 1, 6 weeksPain Visual Analog Scale.
Range of motion6 weeks, 3 months, 6 months, 12 monthsKnee range of motion measurements.
Tegner ScoreBaseline, 3, 6 and 12 months post treatmentReturn to pre injury activity level as measured by the Tegner Score.

Other

MeasureTime frameDescription
Second look arthroscopyif applicableIf a second look arthroscopy is performed, the status of the meniscus (healed or not healed) will be compared to the MRA findings. Second look arthroscopy will be performed on subjects with clinical indication of a failed meniscal repair. Clinical indications of failed meniscus repair include persistent pain and symptoms or MRA positive for a meniscus repair.

Countries

Canada

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026